Resistance Plus ® MG FleXible
M. genitalium+ macrolide resistance detection
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
product image
10 Tests
Unit price
Product is not available for purchase in your region.
Collection devices
product image
ASWAB Dual Swab Specimen Collection Kit (Pack of 50)
Unit price
Product is not available for purchase in your region.
product image
Urine Collection Kit (Pack of 50)
Unit price
Product is not available for purchase in your region.
Error adding items to cart. If this error persists, please contact Digital Support

The Need

M. genitalium is a recognised Sexually Transmitted Infection (STI), treated syndromically, with clinical presentation similar to that of Chlamydia trachomatis.1
Prevalence of M. genitalium infections in the general population ranges from 1-4%2, and its treatment is challenging due to high levels of macrolide resistance.5
  • Macrolide resistance testing is recommended by international and local guidelines on management of M. genitalium infections.3,4,6-8
  • Macrolide resistance testing can guide appropriate treatment choice enabling Resistance Guided Therapy.6
  • Resistance Guided Therapy is clinically demonstrated to improve patient cure rate and overall patient management.9
  • Fast detection of macrolide resistance can reduce time to cure, preventing ongoing transmission.9
1.Manhart LE and Kay N.Mycoplasma genitalium: Is It a Sexually Transmitted Pathogen? Curr. Infect. Dis. Reps. 2010; 12(4):306-313.
2. Cools et al, Lancet Infectious DiseasesVol. 20No. 11p1222–1223
3. 2018 BASHH UK national guideline for the management of infection withMycoplasma genitalium. Available online at
4. Jensen et al. 2016 European guideline onMycoplasma genitalium infections. J Eur Acad Dermatol Venereol. 2016 Oct;30(10):1650-1656.
5. Unemo, M et al. Antimicrobial-resistant sexually transmitted infections: gonorrhoea andMycoplasma genitalium.Nat Rev Urol. 2017 Mar;14(3):139-152.
6. Horner PJ et al. 2016 European guideline on the management of non-gonococcal urethritis. Int J STD AIDS. 2016 Oct;27(11):928-37.
7. Australian STI Management Guidelines – Mycoplasma genitalium 2018.
8. Groupe Infectiologie Dermatologique et Infections Sexuellement GRIDIST and Société Fançaise de Dermatologie – Press Release. Available online at:
9. Read TRH et al. Outcomes of Resistance-guided Sequential Treatment of Mycoplasma genitalium Infections: A Prospective Evaluation. Clin Infect Dis. 2019 Feb 1;68(4):554-560.

The Solution

  • ResistancePlus® MG FleXible detects both M. genitalium and macrolide resistance in ~ 2 hours.
  • ResistancePlus® MG FleXible offers a fast and simple solution in combination with GeneXpert®Systems. Easily implemented into your existing workflow or setting, with minimal preparation time ~ 10 mins.
  • High performance test validates a wide range of specimen types and collection devices, including urine and swabs (vaginal, cervical, rectal).**
**Validated specimens: male and female urine, vaginal swab, cervical swab, rectal swab, urethral swab, from symptomatic and asymptomatic patients. Validated collectionkits: Xpert® Vaginal/Endocervical and Xpert® Urine Specimen CollectionKits, Neat urine, Regular FLOQSwab™ in 3 ml of UTM™ media, cobas PCR collection media. For details refer to theResistancePlus®MG FleXible Instructions For Use (IF-IV0012)

The Impact

Improving patient management

ResistancePlus®MG FleXible provides therapeutic guidance recommendations, enabling clinicians to make informed treatment decisions. Resistance guided therapy is clinically demonstrated to increase overall patient cure rate.9

ResistancePlus®MG FleXible is validated on a wide range of sample types including rectal, male and female urine, and common collection swab kits including Xpert®CT/NGVaginal/Endocervical Specimen Collection kit and Xpert®CT/NG Urine Specimen Collection Kit.**
CE-IVDin VitroDiagnostic Medical Device. Not available in all countries.
*Exclusively distributed by Cepheid under the FleXible by GeneXpert® System program
ResistancePlus® MG FleXible tests are developed and manufactured by SpeeDx Pty Ltd, Sydney. PlexPCR® &ResistancePlus® are trademarks of SpeeDx Pty Ltd. Other copyright and trademarks are theproperty of the respective owners. SpeeDx Pty Ltd productsmaybe covered by oneormore localor foreign comprehensivepatentinformation